The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Open accessAbstract
DNMT3A deletion preserves CAR T cell functionality during prolonged stimulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another study evaluated the effect of DNMT3A loss on CAR-T cells and showed that these cells had an increased ability to proliferate without acquiring a canonical exhaustion phenotype in the context of chronic stimulation [79].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 34,873
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationMachine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
Cited by
Sorted by citations
Items 201–300 of 349
Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy
Zheng, Y., Zhu, Q., Li, X., Ge, T., Wang, S., Jia, R., Yang, L., Wang, Y., & Zhuang, A. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108649 · Cited by 7
Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications
Wu, D., Ju, D., Zhao, Y., Liu, W., Liu, Q., & Liang, Y. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633338 · Cited by 7
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome
Wachsmann, T. L. A., & Qi, L. S. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.001 · Cited by 8
Ali, A. M., Özdemirli, M., Hamilton, M. P., & Jain, M. D. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01147-w · Cited by 7
Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies
Ward, M. B., Jones, A. B., & Krenciute, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001070 · Cited by 7
Self-citationThe impact of epigenetic modifications on allogeneic hematopoietic stem cell transplantation
Ktena, Y. P., Dionysiou, M., Gondek, L. P., & Cooke, K. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188853 · Cited by 7
Toward the clinical development of synthetic immunity to cancer
Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 9
Hoyt-Miggelbrink, A. M., Polania, J. W., Wachsmuth, L. P., Lorrey, S., Mohan, A. A., Hardigan, A. A., Blandford, E. E., Lerner, E., Wilkinson, D. S., Hotchkiss, K. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3455 · Cited by 6
Fumagalli, M., An, D., Simula, L., Combe, C., Aziez, L., Simoni, Y., Alves‐Guerra, M., Valentini, A., Marchais, M., Vermare, A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.009 · Cited by 6
Epigenetic, epitranscriptomic, and metabolic control of T cell exhaustion
Slater, C. J., Simon, A., Laprie-Sentenac, M., & Menger, L. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.03.002 · Cited by 6
Per-cell histone acetylation is associated with terminal differentiation in human T cells
Cheng, Y., Li, Y., Hu, Y., Li, Q., Li, Y., & Li, Y. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01634-w · Cited by 6
Rodriguez, J. E., Baldini, C., Bayle, A., Pagès, A., Danlos, F., Vasseur, D., Rouleau, É., Lacroix, L., de Castro, B. A., Goldschmidt, V., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00631 · Cited by 6
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer
Yao, C., & Davis, K. L. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10232-4 · Cited by 6
Arena, G., & Chiarle, R. (2025) · Cancers · doi:10.3390/cancers17213453 · Cited by 5
Fang, C., Wang, L., Zhao, W., Wang, L., Huang, W., Chen, Z., Wang, Y., Tan, K., Xiao, G., Xu, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07106-w · Cited by 5
pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication
Shi, Y., Lopez, M. A., Kotchetkov, I. S., Jain, N., Zhao, Z., Halim, L., Dobrin, A., Perica, K., Hanina, S., Rajasekhar, V. K., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.005 · Cited by 6
Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma
Zhang, S., Liu, J., & Li, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1696105 · Cited by 5
Epigenetic editing to advance CAR T cell therapy
Horvathova, L., Rots, M. G., & Wiersma, V. R. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02085-1 · Cited by 5
Population dynamics and gene regulation of T cells in response to chronic antigen stimulation
Hsiung, S., & Egawa, T. (2022) · International Immunology · doi:10.1093/intimm/dxac050 · Cited by 6
Talleur, A. C., Naik, S., & Gottschalk, S. M. (2023) · Hematology · doi:10.1182/hematology.2023000424 · Cited by 5
Self-citationSomatic mutations associate with clonal expansion of CD8 + T cells
Lundgren, S., Myllymäki, M., Järvinen, T., Keränen, M. A. I., Theodoropoulos, J., Smolander, J., Kim, D., Salmenniemi, U., Walldin, G., Savola, P., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj0787 · Cited by 8
Detection and Characterization of Clonal Hematopoiesis
Locher, B. N., Löwe, P., Christen, F., & Damm, F. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4188-0_20 · Cited by 6
Solid tumours: Building bridges to CAR‐T success
Maher, J. F. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.179 · Cited by 5
Shams, F., Sharif, E., Abbasi‐Kenarsari, H., Hashemi, N., Hosseini, M. S., Heidari, N., Noori, E., Amini, A. H., Bazrgar, M., Rouhani, M., et al. (2025) · Current Gene Therapy · doi:10.2174/0115665232357078250331180413 · Cited by 6
Challenges and opportunities of CAR T-cell therapies for CLL
Zhao, Z., Grégoire, C., de Oliveira, B. C., Chung, K., & Melenhorst, J. J. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.01.002 · Cited by 5
Optimizing CAR-T Therapy for Glioblastoma
Tang, O. Y., Binder, Z. A., O’Rourke, D. M., & Bagley, S. J. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00671-0 · Cited by 5
Immunotherapy in chronic lymphocytic leukemia: advances and challenges
Gao, P., Zhang, Y., Ma, J., & Zhang, Y. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00644-5 · Cited by 4
Strategies of AI ‐Driven CAR ‐T Cell Therapy Towards Solid Tumours
Abdalla, A. M. E., Miao, Y., Taha, Y. A., Meng, N., & Ouyang, C. (2026) · Immunology · doi:10.1111/imm.70124 · Cited by 4
Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors
Pérez-Criado, I., Figols, M., Moya-Sevilla, A., Bautista, A., Gómez-Díaz, D., Pous, A. F., Martín-Liberal, J., & de Porras, V. R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04383-9 · Cited by 4
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
Grigg, S. E., Shembrey, C., Fareh, M., Blombery, P. A., Corn, J. E., Seymour, J. F., & Casan, J. M. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01179-2 · Cited by 4
Baysal, M. A., Chakraborty, A., & Tsimberidou, A. M. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.080 · Cited by 4
The road ahead for chimeric antigen receptor T cells
Stewart, C. M., Siegler, E. L., & Kenderian, S. S. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf047 · Cited by 4
Castro, V. D., Abdellaoui, O., Dehecq, B., Ndao, B., Mercier‐Letondal, P., Dauvé, A., Garnache‐Ottou, F., Adotévi, O., Loyon, R., & Godet, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04065-5 · Cited by 4
Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism
Zhang, H., Gao, J., Zhang, Z., & Zhang, B. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2560798 · Cited by 3
Chat, V., Fletez‐Brant, K., Srivastava, M. K., Nabet, B. Y., Mellman, I., McCarthy, M. I., & Hammer, C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011565 · Cited by 3
Yu, M., Yang, T., Ding, S., & Hu, Y. (2025) · American Journal of Hematology · doi:10.1002/ajh.70131 · Cited by 3
Lan, F., Song, J., Chen, X., & (9093), Y. Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.02.011 · Cited by 3
Yi, R., Zhang, Z., Yang, Y., & Zhu, H. (2026) · Cancer Innovation · doi:10.1002/cai2.70053 · Cited by 3
Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders
Ren, X., Zhou, Z., Kong, L., Guo, Y., Liu, Y., Li, J., Gu, X., Jiang, C., & Wu, J. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108921 · Cited by 3
Yang, Q., Wang, S., Liu, F., Yu, Y., & Zhao, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847986 · Cited by 3
Adeshakin, A. O., Shi, H., Perry, S. S., Sheppard, H., Nguyen, P., Sun, X., Zhou, P., Métais, J., Cunningham, T., Anil, K. C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103008 · Cited by 4
Self-citationvan den Broecke, L., der Vreken, A. V., Watté, F., Meeus, F., Veirman, K. D., Breckpot, K., Bruyne, E. D., & Menu, E. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02923-x · Cited by 3
Challenges facing CAR T-cell immunotherapy in multiple myeloma
Ouyang, W., & Mi, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104803 · Cited by 3
Multiplex engineering and multifunction T cells for precise and effective immunotherapies
Jafarzadeh, L., Smaani, A., & Delisle, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680410 · Cited by 3
What Is Next in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Talleur, A. C., Pui, C., & Karol, S. E. (2023) · Lymphatics · doi:10.3390/lymphatics1010005 · Cited by 3
Li, T., Cui, Q., Liu, S., Li, Z., Cui, W., Li, M., Ma, Y., Cao, X., Zhu, X., Kang, L., et al. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107569 · Cited by 3
T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy
Zebley, C. C., & Youngblood, B. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.008 · Cited by 3
Self-citationMuller, B., & Inaba, H. (2023) · Translational Pediatrics · doi:10.21037/tp-23-366 · Cited by 3
Alli, R., & Youngblood, B. (2026) · Nature Immunology · doi:10.1038/s41590-026-02443-4 · Cited by 3
Self-citationUnleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy
Zeng, J., Sun, Y., Fang, Y., Wang, X., Huang, Q., Zhang, P., Shao, M., Wang, P., Cheng, J., Di, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541653 · Cited by 2
Zheng, B. J., He, J., Hu, W., Cao, Q., & Li, R. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189442 · Cited by 2
Recapitulating the qualities of HIV-specific CD8+ T cells from spontaneous controllers
DeLucas, K., Blankson, J. N., & Rutishauser, R. L. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001017 · Cited by 2
Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions
Han, S. Z., Yue, J., Zheng, H., Huang, Y., Kong, D., Wei, G., Hu, Y., & Huang, H. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3061-8 · Cited by 2
Targeting epigenetic regulators to boost T cell immunotherapy against cancer
Xiao, T., & Zhang, Y. E. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01533-y · Cited by 2
Manufacturing strategies for prolonged CAR-T cell persistence
Shimasaki, N. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102778 · Cited by 2
Wang, C., Guo, Y., Han, F., Zhang, Y., Liu, C., Wu, Z., Tong, C., Yang, Q., Lu, Y., Zhong, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72040-4 · Cited by 2
Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy
Fourfouris, T., Lee, K. J., Hurwitz, S., Ahdoot, A., Lee, A., Zarrabi, M., Kahn, M., & Kim, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843548 · Cited by 2
Cellular mechano-memory informs biomaterials and mechano-medicine
Qiao, P., Zhao, H., Ma, Z., Hasani, M., & Song, Y. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103308 · Cited by 2
Jurgens, E. M., Mitra, S., Herrera, K., Nemirovsky, D., Bready, B., Derkach, A., Hosszu, K., McAvoy, D. P., Firestone, R., Rajeeve, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed0039 · Cited by 2
Self-citationOptimisation de l’efficacité et de la sécurité d’utilisation des lymphocytes CAR-T
Lew‐Derivry, L., Lamrani, L., Alcantara, M., & Alanio, C. (2024) · médecine/sciences · doi:10.1051/medsci/2024058 · Cited by 2
Optimizing Adoptive Cell Therapy for Solid Tumors via Epigenetic Regulation of T‐cell Destiny
Guo, X., Li, X., Wang, S., Shi, Y., Huang, J., Liu, X., Lu, Y., Zhang, J., Luo, L., & You, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402209 · Cited by 2
Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies
Biernacki, M. A., & Bleakley, M. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2441962 · Cited by 2
Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
Dukes, M. W., & Krenciute, G. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101080 · Cited by 2
Self-citationThe invisible hand: How epigenetics shapes CAR T cell destiny
Ali, A. M., Zhang, Y., & DiPersio, J. F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.007 · Cited by 2
Precision medicine with car cells in acute myeloid leukemia: where are we?
Zanetti, L. C., Tomaz, V., de Souza, I. F., Campregher, P. V., Hamerschlak, N., & Kerbauy, L. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1653350 · Cited by 2
Kouakanou, L., Wang, H., Sun, G. Y., Chan, T., Shepphird, J. K., Alizadeh, D., Brown, C. E., & Wang, L. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0351 · Cited by 2
Self-citationZebley, C. C., & Youngblood, B. (2022) · Science · doi:10.1126/science.adf0546 · Cited by 2
Self-citationSpecial Issue “The Promising Future of CAR-Based Therapies: A Matter of Molecular Details”
Nicolini, F., Montini, O., Zurlo, M., Tettamanti, S., & Mazza, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199587 · Cited by 2
Reprogramming CAR T-Cells with designed bioPROTACsPreprint
Peche, V. S., Kenny, S., Kang, T. G., Coventry, B., Mi, T., Goreshnik, I., Sanchez, M. G., Martin, R., Smith, M., Vafeados, D. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.21.706835 · Cited by 2
Self-citationBreastfeeding During Pregnancy: Opinions and Behaviors of Mothers
KARAMAN, P. D., & Özsoy, S. (2025) · Bezmialem Science · doi:10.14235/bas.galenos.2024.12599 · Cited by 1
Karimi, A., Kazemi-Harikandei, S.-Z., Alilou, S., Salabat, D., Pourfaraji, S. M., Shirmard, F. O., Seighali, N., Maleki, S., Akbari, B., Noorbakhsh, F., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04090-5 · Cited by 1
Raza, M., Haspel, N., Sharma, A., Choi, S. H., Luna, X. D., & Evans, J. J. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109279 · Cited by 1
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
Litvin, R. F. D. A., & Hill, B. T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2621889 · Cited by 1
Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies
Ogusuku, I. E. Y., Knelangen, N., Engels, B., Subklewe, M. S., & Lock, D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.006 · Cited by 1
Post‐Translational Regulation of CD8 + T Cell Fate and Dysfunction in Tumor Immunity
Zhou, Z., Chen, X., Li, N., Zou, M., Lin, Y., Lin, P., Feng, W., Zhao, X., & Cui, L. (2026) · Advanced Science · doi:10.1002/advs.74807 · Cited by 1
RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs
Ibañez-Vega, J., Teis, R., Ocasio, J. K., Chockley, P. J., Ansari, A., Anido, A. A., Mehta, S., Meehl, M. M., Prinzing, B. L., Ward, M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013134 · Cited by 1
Self-citationProgress in cell-based immunotherapies for solid tumors
Zhang, L., Zhang, D., & Wang, B. (2026) · Discover Oncology · doi:10.1007/s12672-026-05092-z · Cited by 1
Perspectives on the Development of Immune Memory Associated with Vaccination
He, P., Zhou, Y., Yu, F., Zhou, T., Li, F., Mi, Y., Zhang, W., & Zhu, B. (2026) · Vaccines · doi:10.3390/vaccines14050420 · Cited by 1
Kim, J.-H., Cho, H. J., & Lee, H. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154003 · Cited by 1
Fujita, T., Ishibashi, N., Aoyama, S., Kobayashi, Y., Kamatani, T., Kinugasa, Y., & Ikeda, S. (2026) · Cancer · doi:10.1002/cncr.70398 · Cited by 1
Atilla, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1863485 · Cited by 1
Liu, Y., Du, W., & Deng, W. (2026) · International Reviews of Immunology · doi:10.1080/08830185.2026.2687543 · Cited by 1
Targeting the fate of exhausted CD8+ T cells
Utzschneider, D. T., & Turner, S. T. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.07.002 · Cited by 1
Mai, Y., Wang, Z., Wang, J., Song, M., Xiang, T., He, Y., Chang, A. H., & Zhang, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00822-z · Cited by 1
PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway
Srour, N., Luo, K., Allard, D., Xiong, Y., Yu, Z., Papadopoulos, T., Santinon, F., Hsieh, C.-H., Parent, A., Stagg, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77155-2 · Cited by 1
The Road Less Traveled: T Cell-Engaging Immunotherapies for Myeloid Malignancies
Wong, Z. C., & Psaila, B. (2025) · The Hematologist · doi:10.1182/hem.v22.1.2025211 · Cited by 1
1405 A CRISPR-Cas9 screen identifies novel epigenetic regulators of T cell exhaustion
Bommakanti, G., Jaensch, E. S., Gorthi, A., Tan, S. L., Brucklacher-Waldert, V., Criscione, S. W., & Mele, D. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1405 · Cited by 1
L’ingénierie cellulaire au service de l’optimisation des CAR-T cells
Galatioto, A., Fredon, M., & Galaine, J. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.07.005 · Cited by 1
Genetics and Epigenetics of Type 1 Diabetes Self-Reactive T CellsPreprint
Kang, T. G., & Youngblood, B. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041586 · Cited by 2
Self-citationKhalil, M., & Tsao, M. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.009 · Cited by 1
Base-editing a single missense mutation in A20 enhances CAR-T cell efficacyPreprint
Blaisdell, A., Bachl, S., Sandoval, L. R., Ching, C., Bowman, C., Kale, N., Prabandham, M., Diolaiti, M. E., Havig, C. C., Advincula, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.05.680562 · Cited by 1
Klonale Hämatopoese – Bedeutung für die Zelltherapie
Teipel, R., Bonin, M. V., Stölzel, F., Schetelig, J., Thiede, C., & Bornhäuser, M. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01403-y
Tapping the keg of discovery to advance T cell therapy
Schulz, A. M., Zebley, C. C., Youngblood, B., & Zehn, D. (2023) · Nature Immunology · doi:10.1038/s41590-022-01401-0
Self-citationO'Connell, C. L., Baer, M. R., Ørskov, A. D., Saini, S. K., Duong, V. H., Kropf, P. L., Hansen, J. W., Tsao-Wei, D. D., Jang, H. J., Emadi, A., et al. (2023) · doi:10.1158/1078-0432.22489683
Self-citationFuture Prospects for Targeting the Epigenome in Lymphomas
Isshiki, Y., & Melnick, A. M. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch17
Pan-cancer analysis of DNMT3A as a robust prognostic biomarker to predict the immunotherapy responsePreprint
Su, X., Liu, J., Tu, Z., Ji, Q., Li, J., & Liu, F. (2023) · Research Square · doi:10.21203/rs.3.rs-3149495/v1
Slavkovic‐Lukic, D., Fioravanti, J., Martín-Santos, A., Han, E., Zhou, J., & Gattinoni, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3593-3_11
Ma, Y., Dai, H., Cui, Q., Liu, S., Kang, L., Lian, X., Cui, W., Yin, J., Liu, L., Cai, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22620311
Ma, Y., Dai, H., Cui, Q., Liu, S., Kang, L., Lian, X., Cui, W., Yin, J., Liu, L., Cai, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22620314
Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Prüß, A., Schmueck‐Henneresse, M., Volk, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22688654
Metadata
- Authors
- Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., Brown, C., Boi, S. K., Alli, S., Crawford, J. C., Riberdy, J. M., Park, J. J., Zhou, S., Velasquez, M. P., DeRenzo, C., Lazzarotto, C. R., Tsai, S. Q., Vogel, P., Pruett-Miller, S. M., Langfitt, D. M., Gottschalk, S., Youngblood, B., & Krenciute, G.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Department of Hematology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.
- Department of Cell and Molecular Biology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.
- Corresponding author
- Prinzing, Brooke
- Zebley, Caitlin C.
- Petersen, Christopher T.
- Gottschalk, Stephen
- Youngblood, Ben
- Krenciute, Giedre
- ORCID
- Prinzing, Brooke
- Zebley, Caitlin C.
- Fan, Yiping
- Anido, Alejandro Allo
- Yi, Zhongzhen
- Nguyen, Phuong
- Houke, Haley
- Bell, Matthew
- Haydar, Dalia
- Brown, Charmaine
- Boi, Shannon K.
- Alli, Shanta
- Crawford, Jeremy Chase
- Riberdy, Janice M.
- Park, Jeoungeun J.
- Zhou, Sheng
- Velasquez, Mireya Paulina
- DeRenzo, Chris
- Lazzarotto, Cicera R.
- Tsai, Shengdar Q.
- Vogel, Peter
- Pruett-Miller, Shondra M.
- Langfitt, Deanna M.
- Gottschalk, Stephen
- Youngblood, Ben
- Krenciute, Giedre
- Venue
- Science Translational Medicine
- Published
- 2021-11-17
- Volume
- 13
- Issue
- 620
- Pages
- eabh0272-eabh0272
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC8733956
- OpenAlex
- W3213155546
- Cited by
- 349
- References
- 84
- Citations by year
- 2026: 68 · 2025: 78 · 2024: 83 · 2023: 82 · 2022: 37 · 2021: 1
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R50CA211481, K99CA256262, F31CA250401, R01CA173750, R00CA256262, P01CA096832, P30CA021765, R01CA237311)
- National Institute of Allergy and Infectious Diseases (R01AI114442, U01AI157189, UM1AI109565)
- National Institute of Neurological Disorders and Stroke (R01NS106379, R01NS121249)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, T cell exhaustion, DNMT3A, DNA methylation, epigenetic repression, IL-10, CD28, CCR7, TCF1, LEF1, antitumor immunity, T cell stemness, epigenetic silencing
- MeSH terms
- Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, CD28 Antigens, Xenograft Model Antitumor Assays, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
